NCT04440735View on ClinicalTrials.gov

A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

October 7, 2020

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Advanced Solid TumorNon Small Cell Lung CancerColorectal Cancer
Interventions
BIOLOGICAL

DSP107

DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.

BIOLOGICAL

Atezolizumab

Atezolizumab is a humanized IgG1 monoclonal antibody that targets PD-L1

Trial Locations (7)

15232

UPMC Hillman Cancer Center University of Pittsburgh, Pittsburgh

19107

SKCC-Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia

32746

Florida Cancer Specialists, Lake Mary

46202

Indiana University Simon Cancer Center, Indianapolis

66204

KUCC / KUMCRI University of Kansas Cancer Center, Kansas City

80045

University of Colorado Hospital, Anschutz Cancer Pavilion (ACP), Aurora

92093

Moores Cancer Center, UCSD, La Jolla

Sponsors

Lead Sponsor

Kahr Medical
All Listed Sponsors
lead

Kahr Medical

INDUSTRY